| Literature DB >> 30506427 |
Eik Dybboe Bjerre1, Klaus Brasso2, Anders Bojer Jørgensen3, Thomas Hindborg Petersen3, Alexandra Röthlin Eriksen3, Anders Tolver4, Jesper Frank Christensen5, Mads Hvid Poulsen6,7, Søren Sørensen Madsen8, Peter Busch Østergren9, Michael Borre10, Peter Krustrup11,12, Christoffer Johansen13,14, Mikael Rørth15, Julie Midtgaard3,16.
Abstract
BACKGROUND: Physical activity has been shown to mitigate the unwanted psychological and physiological side effects of prostate cancer treatments, but sustainable exercise possibilities are limited.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30506427 PMCID: PMC6349963 DOI: 10.1007/s40279-018-1031-0
Source DB: PubMed Journal: Sports Med ISSN: 0112-1642 Impact factor: 11.136
Fig. 1Flow of participants. DXA Dual-energy X-ray absorptiometry, Pca prostate cancer, () DXA lost to follow up
Baseline characteristics of patients according to allocation group
| Characteristic | FG ( | UG ( | Total ( |
|---|---|---|---|
| Age (years) | 67.8 ± 6.2 | 69.0 ± 6.2 | 68.4 ± 6.2 |
| Employment status | |||
| Paid work | 26 (24) | 26 (25) | 52 (24) |
| Unemployed | 2 (2) | 0 (0) | 2 (1) |
| Sick leave | 1 (1) | 2 (2) | 3 (1) |
| Retired | 80 (73) | 77 (73) | 157 (73) |
| Education | |||
| No education | 7 (6) | 5 (5) | 12 (6) |
| Primary education (9th/10th grade) | 4 (4) | 5 (5) | 9 (4) |
| Vocational education | 33 (30) | 28 (27) | 61 (29) |
| Secondary education (12th grade) | 10 (9) | 15 (14) | 25 (12) |
| Completed college or higher | 55 (50) | 52 (50) | 107 (50) |
| Marital status | |||
| Married or living with partner | 92 (84) | 93 (89) | 185 (86) |
| Other (single, divorced, or widowed) | 17 (16) | 12 (11) | 29 (14) |
| Smoking status | |||
| Yes | 17 (16) | 11 (10) | 28 (13) |
| No, stopped | 49 (45) | 51 (49) | 100 (47) |
| No, never | 43 (39) | 43 (41) | 86 (40) |
| Alcohol consumption (drinks per week) | 9.1 ± 7.2 | 8.5 ± 7.0 | 8.8 ± 7.1 |
| Time since diagnosis, years | 3.0 ± 2.7 | 3.8 ± 3.9 | 3.4 ± 3.4 |
| Risk group | |||
| Localized, prostatectomized | 16 (15) | 15 (14) | 31 (14) |
| Localized, not prostatectomized | 27 (25) | 28 (27) | 55 (26) |
| Locally advanced | 39 (36) | 42 (40) | 81 (38) |
| Metastatic | 26 (24) | 19 (18) | 45 (21) |
| Unknown | 1 (1) | 1 (1) | 2 (1) |
| ISUP Gleason Grading | |||
| Group 1 (Gleason score 2–6) | 15 (14) | 13 (12) | 28 (13) |
| Group 2 (Gleason score 3 + 4) | 29 (27) | 36 (34) | 65 (30) |
| Group 3 (Gleason score 4 + 3) | 18 (17) | 13 (12) | 31 (14) |
| Group 4 (Gleason score 8) | 18 (17) | 13 (12) | 31 (14) |
| Group 5 (Gleason score 9–10) | 28 (26) | 24 (23) | 52 (24) |
| Unknown | 1 (1) | 6 (6) | 7 (3) |
| Number of men with bone metastasis | 22 (20) | 19 (18) | 41 (19) |
| Current treatment at baseline | |||
| No treatmenta | 46 (42) | 42 (40) | 88 (41) |
| Anti-androgen monotherapy | 15 (14) | 21 (20) | 36 (17) |
| Castration (surgical or pharmacological) | 46 (42) | 41 (39) | 87 (41) |
| Unknown | 2 (2) | 1 (1) | 3 (1) |
| Previous treatment at baseline | |||
| Prostatectomy | 27 (25) | 39 (37) | 66 (31) |
| Radiation | 37 (34) | 29 (28) | 66 (31) |
| ADT and radiation with curative intent | 21 (19) | 16 (15) | 37 (17) |
| Chemotherapy (docetaxel) | 9 (8) | 10 (10) | 19 (9) |
| No prior or current treatment | 21 (20) | 24 (22) | 45 (21) |
| Time on ADT, median days ( | 512.5 (208–881) | 580 (235–1089) | 520 (213–982) |
| Number of comorbidities | |||
| Zero | 35 (32) | 29 (28) | 64 (30) |
| One | 45 (41) | 46 (44) | 91 (43) |
| Two | 16 (15) | 18 (17) | 34 (16) |
| Three or more | 13 (12) | 12 (11) | 25 (12) |
| Baseline values on outcomes | |||
| Prostate cancer-specific QoL (FACT-P, points) | 123.7 ± 17.3 | 124.6 ± 16.6 | 124.1 ± 16.9 |
| Lean body mass (kg) | 56.6 ± 6.3 | 57.5 ± 7.1 | 57.0 ± 6.7 |
| Fat mass (kg) | 27.5 ± 8.0 | 28.3 ± 8.9 | 27.9 ± 8.4 |
| Whole-body BMC (kg) | 3.1 ± 0.5 | 3.1 ± 0.6 | 3.1 ± 0.5 |
| Whole-body BMD (g/cm2) | 1.215 ± 0.116 | 1.219 ± 0.125 | 1.217 ± 0.120 |
| Femoral neck BMD (g/cm2) | 0.877 ± 0.155 | 0.877 ± 0.147 | 0.877 ± 0.151 |
| Total hip BMD (g/cm2) | 1.015 ± 0.132 | 1.025 ± 0.138 | 1.020 ± 0.134 |
| Lumbar BMD (g/cm2) | 1.188 ± 0.226 | 1.189 ± 0.223 | 1.188 ± 0.224 |
| Weekly self-reported PA (median MET)b | 3649 (1824–6693) | 4098 (2394–7732) | 4046 (2010–6845) |
Data are presented as mean ± standard deviation, n (%) or median (interquartile range)
ADT androgen-deprivation therapy, BMC bone mineral content, BMD bone mineral density, FACT-P Functional Assessment of Cancer Therapy-Prostate questionnaire, FG football group, ISUP International Society of Urological Pathology, MET metabolic equivalent task, PA physical activity, QoL quality of life, UG usual care group
aWatchful waiting, active surveillance, previous prostatectomy, or radiation
b102 patients in the FG and 96 patients in the UG
Fig. 2Mean change in outcomes, according to allocation group and time points. QoL quality of life, BMD bone mineral density
Outcomes for the intention-to-treat population according to group allocation
| FG ( | UG ( | Covariance analysis, difference between groups | Unadjusted analyses, | |||||
|---|---|---|---|---|---|---|---|---|
|
| Mean (95% CI) |
| Mean (95% CI) | Adjusted for ADT, age, and baseline score | Unadjusted | |||
| Change in prostate cancer-specific quality of life (points; higher is better) | ||||||||
| 12 weeks | 106 | − 0.5 (− 2.6 to 1.5) | 104 | − 2.5 (− 4.6 to − 0.4) | 1.9 (− 1.0 to 4.8) | 0.20 | 2.0 (− 0.9 to 4.9) | 0.18 |
| 6 months | 100 | − 1.2 (− 3.6 to 1.2) | 100 | − 1.7 (− 4.1 to 0.6) | 0.5 (− 2.8 to 3.8) | 0.76 | 0.5 (− 2.8 to 3.9) | 0.76 |
| Change in lean body mass (kg) | ||||||||
| 6 months | 104 | − 0.2 (− 0.5 to 0.1) | 100 | − 0.1 (− 0.4 to 0.2) | − 0.1 (− 0.6 to 0.3) | 0.60 | − 0.1 (− 0.6 to 0.4) | 0.66 |
| Change in fat mass (kg) | ||||||||
| 6 months | 104 | − 0.3 (− 0.7 to 0.2) | 100 | 0.0 (− 0.4 to 0.4) | − 0.3 (− 0.9 to 0.3) | 0.28 | − 0.2 (− 0.8 to 0.3) | 0.42 |
| Change in whole-body bone mineral content (g) | ||||||||
| 6 months | 104 | 8.9 (− 5.1 to 22.8) | 100 | 4.3 (− 9.9 to 18.5) | 3.2 (− 16.9 to 23.3) | 0.75 | 4.5 (− 15.3 to 24.4) | 0.65 |
| Change in whole-body BMD (g/cm2) | ||||||||
| 6 months | 104 | 0.002 (− 0.002 to 0.007) | 100 | 0.001 (− 0.003 to 0.006) | 0.001 (− 0.006 to 0.007) | 0.87 | 0.001 (− 0.006 to 0.007) | 0.75 |
| Femoral neck BMD (g/cm2) | ||||||||
| 6 months | 104 | 0.009 (0.003 to 0.016) | 100 | 0.003 (− 0.003 to 0.009) | 0.007 (− 0.002 to 0.016) | 0.12 | 0.007 (− 0.002 to 0.016) | 0.13 |
| Change in total hip BMD (g/cm2) | ||||||||
| 6 months | 104 | 0.001 (− 0.006 to 0.008) | 100 | 0.006 (− 0.002 to 0.013) | − 0.005 (− 0.015 to 0.005) | 0.34 | − 0.004 (− 0.014 to 0.006) | 0.41 |
| Change in lumbar spine L1–L4 BMD (g/cm2) | ||||||||
| 6 months | 104 | 0.014 (0.003 to 0.025) | 99 | 0.011 (0.000 to 0.022) | 0.003 (− 0.013 to 0.019) | 0.72 | 0.003 (− 0.013 to 0.018) | 0.74 |
| Change in weekly physical activity (MET minutes) | ||||||||
| 12 weeks | 96 | 1710 (328 to 3092) | 89 | 638 (− 797 to 2073) | 698 (1158 to 2555) | 0.46 | 1072 (− 920 to 3064) | 0.29 |
| 6 months | 90 | 485 (− 759 to 1729) | 87 | 928 (− 337 to 2193) | − 754 (− 2316 to 808) | 0.34 | − 443 (− 2217 to 1332) | 0.62 |
| Change in general physical health (SF-12) | ||||||||
| 12 weeks | 106 | − 1.5 (− 2.6 to − 0.4) | 104 | − 1.7 (− 2.8 to − 0.6) | 0.1 (− 1.4 to 1.6) | 0.92 | 0.2 (− 1.3 to 1.8) | 0.79 |
| 6 months | 100 | − 2.5 (− 3.8 to − 1.2) | 100 | − 1.3 (− 2.6 to − 0.1) | − 1.1 (− 2.9 to 0.6) | 0.21 | − 1.2 (− 3.0 to 0.6) | 0.20 |
| Change in general mental health (SF-12) | ||||||||
| 12 weeks | 106 | 0.5 (− 0.8 to 1.8) | 104 | − 0.8 (− 2.1 to 0.5) | 1.5 (− 0.2 to 3.3) | 0.08 | 1.3 (− 0.5 to 3.2) | 0.15 |
| 6 months | 100 | 1.1 (− 0.4 to 2.6) | 100 | − 1.5 (− 2.9 to 0.0) | 2.7 (0.8 to 4.6) | 0.01 | 2.6 (0.5 to 4.7) | 0.02 |
Data are presented as n or mean (95% confidence interval) unless otherwise indicated
ADT androgen-deprivation therapy, BMD bone mineral density, CI confidence interval, FG football group, MET metabolic equivalent, SF-12 12-Item Short Form Health Survey, UG usual care group
Fig. 3Weekly MET minutes, according to allocation group. MET metabolic Equivalent
Fig. 4Mean changes in body composition based on baseline physical activity
| Systematic reviews of efficacy trials have shown that exercise is efficacious in improving quality of life, fatigue and exercise capacity. The current evidence base is limited regarding the evaluation of effectiveness of exercise strategies that can be sustained in the long term. |
| The results of this trial suggest that football implemented in local clubs for men with prostate cancer is a feasible exercise strategy and yields results comparable to those from being referred to physical activity and rehabilitation. |
| Football was low cost, and a majority of the men continued in the football club after the study period. |